<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ph3" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ph3</book-part-id>
      <title-group>
        <title>Primary Hyperoxaluria Type 3</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Milliner</surname>
            <given-names>Dawn S</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Mayo Clinic<break/>Rochester, Minnesota</aff>
          <email>milliner.dawn@mayo.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Harris</surname>
            <given-names>Peter C</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Mayo Clinic<break/>Rochester, Minnesota</aff>
          <email>harris.peter@mayo.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lieske</surname>
            <given-names>John C</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Mayo Clinic<break/>Rochester, Minnesota</aff>
          <email>lieske.john@mayo.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>24</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ph2" document-type="chapter">Primary Hyperoxaluria Type 2</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="trimethylaminuria" document-type="chapter">Primary Trimethylaminuria</related-object>
      <abstract id="ph3.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical description</title>
          <p>Primary hyperoxaluria type 3 (PH3) is characterized by recurring calcium oxalate stones beginning in childhood or adolescence and, on occasion, nephrocalcinosis or reduced kidney function. In 50%-65% of individuals with PH3 stone formation begins prior to age five years. Although the frequency and severity of stone activity often seem to abate by adolescence and adulthood, stone formation can occur throughout life and some adults have many stones. To date systemic oxalosis has not been reported in PH3.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of PH3 is established in a proband with calcium oxalate kidney stone(s) and/or nephrocalcinosis, urine oxalate &#x0003e;0.7 mmol/1.73 m<sup>2</sup>/24 hours (in those with preserved kidney function), increased concentration of plasma oxalate (particularly in those with reduced kidney function), and biallelic (homozygous or compound heterozygous) pathogenic variants in <italic toggle="yes">HOGA1</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Reduction of urine supersaturation of calcium oxalate by maintaining high oral fluid intake at all times and use of an inhibitor of calcium oxalate crystallization such as potassium or sodium citrate; prevention of stone complications by prompt relief of urinary tract obstruction and treatment of urinary tract infections; and avoidance of marked dietary oxalate excess.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Same as <italic toggle="yes">Treatment of Manifestations.</italic></p>
          <p><italic toggle="yes">Surveillance:</italic> For those who are stable, annual clinical assessment of: stone-related symptoms (pain), frequency of passage of urinary stones and/or gravel, urinary tract infection; adherence to high fluid intake and medication schedule; annual: assessment of kidney function by serum creatinine, measurement of plasma oxalate concentration in those with impaired renal function, 24-hour urine oxalate and supersaturation study, and renal ultrasound examination or other imaging to monitor for stone formation.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Intravascular volume contraction, delays in treatment of acute stone episodes, marked dietary oxalate excess, high-dose ascorbic acid, and nephrotoxic agents.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Presymptomatic diagnosis and treatment is warranted in relatives at risk to reduce stone formation and the risk of nephrocalcinosis and chronic kidney disease.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Adequate fluid intake throughout the pregnancy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>PH3 is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">HOGA1</italic> pathogenic variants in the family are known<italic toggle="yes">.</italic></p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ph3.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ph3.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Primary hyperoxaluria type 3 (PH3) should be considered in any individual with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Recurring calcium oxalate stones</p>
            </list-item>
            <list-item>
              <p>Onset of stone disease in childhood or adolescence</p>
            </list-item>
            <list-item>
              <p>Nephrocalcinosis</p>
            </list-item>
            <list-item>
              <p>Reduced kidney function in the presence of calcium stones or nephrocalcinosis</p>
            </list-item>
            <list-item>
              <p>Family history of chronic kidney disease and/or recurring calcium oxalate stones consistent with autosomal recessive inheritance</p>
            </list-item>
          </list>
          <p>Note: Since idiopathic stone disease is very common [<xref ref-type="bibr" rid="ph3.REF.worcester.2010.954">Worcester &#x00026; Coe 2010</xref>] and since calcium oxalate is found in approximately 80% of stones [<xref ref-type="bibr" rid="ph3.REF.worcester.2010.954">Worcester &#x00026; Coe 2010</xref>], a high index of clinical suspicion is necessary to identify the small proportion of individuals who form calcium oxalate stones as a result of PH3.</p>
        </sec>
        <sec id="ph3.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>Algorithms for the diagnosis of the primary hyperoxalurias have recently been published [<xref ref-type="bibr" rid="ph3.REF.harambat.2011">Harambat et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.edvardsson.2013.1923">Edvardsson et al 2013</xref>] (see <xref ref-type="fig" rid="ph3.F1">Figure 1</xref>).</p>
          <p>The diagnosis of PH3 is established in a proband with the clinical findings of calcium oxalate kidney stone(s) and/or (on occasion) nephrocalcinosis and the following <bold>biochemical</bold> and <bold>molecular genetic</bold> findings.</p>
          <sec id="ph3.Biochemical_Findings">
            <title>Biochemical Findings</title>
            <p><bold>Urine oxalate.</bold> &#x0003e;0.7 mmol/1.73 m<sup>2</sup>/24 hours in individuals with preserved kidney function (GFR &#x0003e;40 mL/min/1.7m<sup>2</sup>)</p>
            <p>Note: (1) Urine oxalate may be lower in individuals with advanced chronic kidney disease (CKD). (2) In children the oxalate excretion rate must be corrected for 1.73 m<sup>2</sup> body surface area (BSA). (3) Urine oxalate should preferably be measured in a 24-hour urine sample; however, when timed urine collections cannot be obtained, a random urine oxalate/creatinine ratio can be used. Since normal ranges for oxalate/creatinine vary during childhood by age, age-related normal values should be consulted for accurate interpretation (see <xref ref-type="table" rid="ph3.T.random_urine_oxalatetocreatinine_o">Table 1</xref>).</p>
            <p><bold>Plasma oxalate.</bold> &#x0003e;20 &#x000b5;mol/L and/or systemic oxalosis in individuals with chronic kidney disease stages 3b, 4, and 5 (GFR &#x0003c;45 mL/min/1.73m<sup>2</sup>)</p>
            <p><bold>Urine glycolate, L-glycerate, 4-hydroxyoxoglutarate (HOG),</bold> and <bold>dihydroxyglutarate (DHG)</bold></p>
            <list list-type="bullet">
              <list-item>
                <p>Increased urine glycolate in the presence of hyperoxaluria is suggestive, but not diagnostic of PH1.</p>
              </list-item>
              <list-item>
                <p>Increased urine L-glycerate in an individual with hyperoxaluria suggests PH2 (see <xref ref-type="sec" rid="ph3.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
              </list-item>
              <list-item>
                <p>Increased HOG and DHG suggest PH3 (see <xref ref-type="sec" rid="ph3.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
              </list-item>
            </list>
            <p>Note: The patient should not be receiving pyridoxine or vitamin supplements when urine and plasma oxalate and urine glycolate measurements are being obtained for the purpose of diagnosis.</p>
            <table-wrap id="ph3.T.random_urine_oxalatetocreatinine_o" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Random Urine Oxalate-to-Creatinine (Ox/Cr) Ratio by Age</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Age</th>
                    <th id="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Upper Limit of Normal (mmol/mmol)&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">(mg/mg)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x0003c;6 months&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0.37</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">0.29</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 months to 2 years</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0.26</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">0.20</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x0003e;2 years to 5 years</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0.14</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">0.11</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 to 12 years</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0.08</td>
                    <td headers="hd_h_ph3.T.random_urine_oxalatetocreatinine_o_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">0.06</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Based on: <xref ref-type="bibr" rid="ph3.REF.gibbs.1969.901">Gibbs &#x00026; Watts [1969]</xref>, <xref ref-type="bibr" rid="ph3.REF.barratt.1991.501">Barratt et al [1991]</xref>, <xref ref-type="bibr" rid="ph3.REF.morgenstern.1993.248">Morgenstern et al [1993]</xref>, <xref ref-type="bibr" rid="ph3.REF.von_schnakenburg.1994.27">Von Schnakenburg et al [1994]</xref></p>
                </fn>
                <fn id="ph3.TF.1.1">
                  <label>1. </label>
                  <p>Urine Ox/Cr ratios are higher in very premature infants than in term infants, especially when they are receiving parenteral nutrition containing amino acids. The ratio falls when premature infants are receiving only glucose and electrolyte solutions [<xref ref-type="bibr" rid="ph3.REF.campfield.1989.860">Campfield &#x00026; Braden 1989</xref>].</p>
                </fn>
                <fn id="ph3.TF.1.2">
                  <label>2. </label>
                  <p>When very high dietary oxalate or low dietary calcium is suspected as the cause of the hyperoxaluria, the diet should be corrected and the urine oxalate remeasured for verification.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="ph3.Molecular_Genetic_Findings">
            <title>Molecular Genetic Findings</title>
            <p>Diagnostic findings are biallelic (homozygous or compound heterozygous) pathogenic variants in <italic toggle="yes">HOGA1</italic> [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2012.1497">Belostotsky et al 2012</xref>] (see <xref ref-type="table" rid="ph3.T.summary_of_molecular_genetic_testi">Table 2</xref>).</p>
            <p>Molecular testing approaches can include <bold>a</bold>
<bold>multi-gene panel</bold> and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
            <p><bold>Multi-gene panel.</bold> Because of the overlapping phenotypes of the three types of primary hyperoxaluria (see <xref ref-type="sec" rid="ph3.Differential_Diagnosis">Differential Diagnosis</xref>), the authors recommend sequencing the coding and flanking intronic regions of <italic toggle="yes">AGXT</italic> (PH1), <italic toggle="yes">GRHPR</italic> (PH2), and <italic toggle="yes">HOGA1</italic> (PH3) [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>, <xref ref-type="bibr" rid="ph3.REF.williams.2015.69">Williams et al 2015</xref>].</p>
            <p>If only one or no pathogenic variant is detected in one of these three genes in an individual whose clinical and laboratory findings strongly suggest PH, gene-targeted deletion/duplication analysis should be performed [<xref ref-type="bibr" rid="ph3.REF.nogueira.2000.384">Nogueira et al 2000</xref>, <xref ref-type="bibr" rid="ph3.REF.monico.2007.1905">Monico et al 2007</xref>]. The finding of only a single pathogenic variant should not be considered diagnostic without additional biochemical evidence (e.g., elevated HOG and DHG).</p>
            <p><bold>More comprehensive genomic testing,</bold> which may be used if no pathogenic variant is detected on a panel of the three PH-related genes, includes a multi-gene panel for a wide range of kidney stone-associated diseases [<xref ref-type="bibr" rid="ph3.REF.halbritter.2015.543">Halbritter et al 2015</xref>] and exome sequencing. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            <table-wrap id="ph3.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Primary Hyperoxaluria Type 3</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">HOGA1</italic>
                    </td>
                    <td headers="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">All pathogenic variants reported to date&#x000a0;<sup>3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ph3.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown (i.e., no data on gene-targeted del/dup analysis are available)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ph3.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ph3" object-id="ph3.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein name. See <xref ref-type="sec" rid="ph3.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="ph3.TF.2.2">
                  <label>2. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="ph3.TF.2.3">
                  <label>3. </label>
                  <p><xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al [2010]</xref>, <xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al [2012]</xref>, <xref ref-type="bibr" rid="ph3.REF.beck.2013.162">Beck et al [2013]</xref>, <xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al [2015]</xref></p>
                </fn>
                <fn id="ph3.TF.2.4">
                  <label>4. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="ph3.Genetically_Related_Allelic_Disorder">
          <title>Genetically Related (Allelic) Disorders</title>
          <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are currently known to be associated with pathogenic variants in <italic toggle="yes">HOGA1</italic>.</p>
        </sec>
      </sec>
      <sec id="ph3.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ph3.Clinical_Description">
          <title>Clinical Description</title>
          <p>Individuals with primary hyperoxaluria type 3 (PH3) most often present in childhood with signs or symptoms related to kidney stones including hematuria, frequent urination, dysuria, blood visible in the urine, or pain associated with a stone.</p>
          <p>Although the stones are likely to be discovered due to symptoms, they may be detected incidentally on imaging studies performed for other purposes.</p>
          <p>Approximately 50%-65% of individuals with PH3 present with a stone prior to age five years [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.matsumoto.2015">Matsumoto &#x00026; Milliner 2015</xref>]. Although the frequency and severity of stone activity appear to abate in adolescence and adulthood [<xref ref-type="bibr" rid="ph3.REF.hoppe.2012.3024">Hoppe 2012</xref>], stone formation can occur throughout life, and some adults have many stones.</p>
          <p>Nephrocalcinosis has been reported to date only occasionally in individuals with PH3 [<xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>, <xref ref-type="bibr" rid="ph3.REF.tang.2015.623">Tang et al 2015</xref>].</p>
          <p>Over time, kidney function may become compromised from frequent stones and/or nephrocalcinosis, resulting in chronic kidney disease (CKD). However, kidney function appears to remain better preserved among individuals with PH3 compared to those with PH1 or PH2 [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>].</p>
          <p>To date, only one individual with PH3 has been reported to progress to end-stage renal disease. In this eight-year-old patient, stone removal procedures and urinary tract obstruction may have contributed to the loss of kidney function [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>].</p>
          <p><bold>Systemic oxalosis</bold>. The plasma concentration of oxalate increases significantly in individuals with PH and advanced CKD. When the plasma oxalate concentration reaches super-saturation, calcium oxalate crystals are deposited in many body tissues. Crystal-induced injury can include cutaneous ulcers, vascular disease, cardiomyopathy, cardiac conduction disturbances, non-healing fractures, erythropoietin- resistant anemia, and retinal deposits [<xref ref-type="bibr" rid="ph3.REF.hoppe.2012.3024">Hoppe 2012</xref>]. Although systemic oxalosis is well recognized in <related-object link-type="booklink" source-id="gene" document-id="ph1" document-type="chapter">PH1</related-object> and seen occasionally in <related-object link-type="booklink" source-id="gene" document-id="ph2" document-type="chapter">PH2</related-object>, it has not been reported to date in PH3, an observation consistent with the infrequency of end-stage renal disease (ESRD) in PH3.</p>
          <p><bold>Heterozygotes.</bold> Although some heterozygotes (carriers) have had elevations of urinary oxalate [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>], this may be coincidental as it is not seen in the majority. As more families are studied, additional information is expected to provide a better understanding of the risk to heterozygotes.</p>
        </sec>
        <sec id="ph3.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Although no differences in phenotypic manifestations were noted among individuals with the two most common <italic toggle="yes">HOGA1</italic> pathogenic variants [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>], the relatively recent discovery of mutation of <italic toggle="yes">HOGA1</italic> as the cause of PH3 and the rarity of PH3 (&#x0003c;100 affected individuals described to date) have limited this type of analysis.</p>
          <p>Families of Ashkenazi Jewish heritage with PH3 have developed hypercalciuria in addition to hyperoxaluria [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.hoppe.2012.3024">Hoppe 2012</xref>]; however, to date no specific genotype-phenotype correlation has been established [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>].</p>
        </sec>
        <sec id="ph3.Prevalence">
          <title>Prevalence</title>
          <p>Surveys of clinicians in central Europe led to estimates of the prevalence of primary hyperoxaluria (of all causes) of 1-3 per million population [<xref ref-type="bibr" rid="ph3.REF.hoppe.2009.1264">Hoppe et al 2009</xref>].</p>
          <p>Among individuals with primary hyperoxaluria approximately 70% have PH1, 10% have PH2, 10% have PH3, and 10% have no as-yet identified genetic cause [<xref ref-type="bibr" rid="ph3.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>, <xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>].</p>
          <p>Registry data of the Rare Kidney Stone Consortium and OxalEurope suggest a prevalence of PH3 that is similar to PH2 and approximately one sixth that of PH1.</p>
          <p>By contrast, estimates from publicly available population data (NHLBI ESP) showed a PH3 carrier frequency of 1:185 [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>] which was similar to the rate observed for PH1, suggesting certain individuals with PH3 either remain undiagnosed or do not have clinical manifestations. Prevalence of PH3 from the genomic data is currently estimated at 1:136,000 [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>].</p>
          <p>PH3 has been observed more commonly among individuals of Ashkenazi Jewish descent [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>]; however, the true prevalence in this population is unknown.</p>
        </sec>
      </sec>
      <sec id="ph3.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Any condition that causes calcium oxalate kidney stone disease or nephrocalcinosis and is associated with hyperoxaluria should be included in the differential diagnosis of primary hyperoxaluria type 3 (PH3).</p>
        <sec id="ph3.Primary_Hyperoxalurias">
          <title>Primary Hyperoxalurias</title>
          <p>The three known types of primary hyperoxaluria (PH) are <related-object link-type="booklink" source-id="gene" document-id="ph1" document-type="chapter">PH1</related-object> (due to mutation of <italic toggle="yes">AGXT</italic>), <related-object link-type="booklink" source-id="gene" document-id="ph2" document-type="chapter">PH2</related-object> (mutation of <italic toggle="yes">GRHPR</italic>), and PH3 (mutation of <italic toggle="yes">HOGA1</italic>). Each gene encodes an enzyme for different metabolic pathways relevant for the metabolism of glyoxylate [<xref ref-type="bibr" rid="ph3.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</xref>]. Oxalate accumulates as an end product in all forms of PH; however, the specific pathways that lead to its accumulation in PH3 require further clarification [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.riedel.2012">Riedel et al 2012</xref>, <xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>].</p>
          <p>Of the primary hyperoxalurias, approximately 70% are PH1, 10% are PH2, 10% PH3, and 10% do not have an identified genetic cause [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>]. The clinical manifestations of the three known types of PH overlap considerably.</p>
          <p>In some individuals with PH3, significant stone manifestations have been observed in infancy and early childhood; these appear to have abated by later childhood or adolescence [<xref ref-type="bibr" rid="ph3.REF.hoppe.2012.3024">Hoppe 2012</xref>, <xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>]</p>
          <p>Urine oxalate excretion rates tend to be lower in individuals with PH3 than in those with PH1 or PH2 [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>]. In PH3 urine oxalate excretion appears to be more variable over time. However, because of the overlap of urinary oxalate excretion in all three types, the type of PH (and thus the diagnosis of PH3) cannot be confirmed on this basis alone [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>].</p>
          <p>Hypercalciuria, observed in a subset of individuals with PH3, is not usually observed in PH1 and PH2 [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>].</p>
          <p>Hyperoxaluria of the degree observed in individuals with primary hyperoxaluria causes deposition of calcium oxalate crystals in the kidney (nephrocalcinosis) associated with inflammation, kidney damage, and often chronic kidney disease and/or end-stage renal disease (ESRD). ESRD appears to be unusual in PH3, having been reported in just one individual to date [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>]; however, modest renal impairment has been described in other cohorts [<xref ref-type="bibr" rid="ph3.REF.allard.2015.1807">Allard et al 2015</xref>].</p>
          <p>Systemic calcium oxalate deposition (systemic oxalosis) may develop due to high levels of plasma oxalate in patients with PH who have advanced CKD. Systemic oxalosis results in varying degrees of organ dysfunction including infiltrative cardiomyopathy, arrhythmias due to involvement of the cardiac conduction system, erythropoietin-resistant anemia due to extensive crystal deposition in the bone marrow, pathologic fractures, and/or retinal oxalate deposition [<xref ref-type="bibr" rid="ph3.REF.hoppe.2009.1264">Hoppe et al 2009</xref>]. Systemic oxalosis has not yet been reported in any individual with PH3, an observation consistent with the infrequency of end-stage renal disease (ESRD) in PH3.</p>
          <p>Differences in urinary metabolites other than oxalate can provide clues regarding the most likely type of PH.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>4-hydroxy-2-oxoglutarate (HOG).</bold> In PH3 urinary levels of HOG are often high, whereas in PH1 and PH2 urinary HOG is undetectable [<xref ref-type="bibr" rid="ph3.REF.riedel.2012">Riedel et al 2012</xref>]. The diagnostic sensitivity and specificity of this finding remain to be determined [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2012.1497">Belostotsky et al 2012</xref>, <xref ref-type="bibr" rid="ph3.REF.riedel.2012">Riedel et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Urinary glycolate</bold> may be elevated in PH1 or occasionally in PH3 [<xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Urine glycerate</bold> is increased in most individuals with PH2; however, exceptions (perhaps related to the sensitivity of the testing process) occur [<xref ref-type="bibr" rid="ph3.REF.rumsby.2001.1697">Rumsby et al 2001</xref>].</p>
            </list-item>
          </list>
          <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS259900">Primary hyperoxaluria: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
          <p><bold>Idiopathic calcium oxalate stone disease</bold> can be associated with mild hyperoxaluria. The hyperoxaluria is typically of a lesser degree (&#x0003c;0.6 mmol/day) than that observed in the primary hyperoxalurias, is variable from one collection to the next, and is frequently associated with mild hypercalciuria.</p>
        </sec>
        <sec id="ph3.Secondary_Hyperoxalurias">
          <title>Secondary Hyperoxalurias</title>
          <p>Secondary forms of hyperoxaluria are not uncommon and should be systematically considered.</p>
          <p><bold>Dietary or other sources of excessive oxalate or oxalate precursors</bold> should be considered in the differential. Very high doses of vitamin C are a potential cause. Exposure to toxins such as ethylene glycol can cause marked hyperoxaluria and associated acute renal failure.</p>
          <p><bold>Enteric hyperoxaluria</bold> results from any cause of fat malabsorption in the small intestine. In the colon, this undigested fat combines with calcium and decreases the amount of calcium available to bind to oxalate. This free oxalate is absorbed. In addition, fatty acids that are not absorbed in the small intestine can damage the colonic mucosa, leading to further increase in oxalate absorption. Thus, any gastrointestinal disease or surgery that impairs fat absorption is a potential cause of enteric hyperoxaluria [<xref ref-type="bibr" rid="ph3.REF.kumar.2011.654">Kumar et al 2011</xref>]. Hyperoxaluria resulting from short bowel syndrome and following malabsorptive types of gastric bypass surgery can be quite marked, overlapping the range seen in inherited PH of all types.</p>
          <p>Medications that interfere with fat absorption from the GI tract (e.g., orlistat) can be associated with hyperoxaluria.</p>
          <p>Marked deficiency of dietary calcium, leaving a greater proportion of oxalate free in the intestinal lumen, can result in increased absorption of oxalate resulting in hyperoxaluria.</p>
          <p><bold>Nephrocalcinosis of prematurity</bold> occurs in a significant proportion of infants born prior to 28 weeks&#x02019; gestation and is characterized by both nephrocalcinosis and nephrolithiasis [<xref ref-type="bibr" rid="ph3.REF.habbig.2011.1278">Habbig et al 2011</xref>]. Risk factors among premature infants thought to contribute to this disease include urine oxalate that is higher than that observed in infants born at term [<xref ref-type="bibr" rid="ph3.REF.schellfeith.2010.221">Schell-Feith et al 2010</xref>] as well as hypercalciuria and hypocitric aciduria. Calcium oxalate crystals have been detected in the renal parenchyma [<xref ref-type="bibr" rid="ph3.REF.schellfeith.2010.221">Schell-Feith et al 2010</xref>]. Since individuals with PH3 can develop stones in infancy or during early childhood [<xref ref-type="bibr" rid="ph3.REF.hoppe.2012.3024">Hoppe 2012</xref>, <xref ref-type="bibr" rid="ph3.REF.matsumoto.2015">Matsumoto &#x00026; Milliner 2015</xref>], there may be confusion with stones or nephrocalcinosis related to prematurity.</p>
        </sec>
      </sec>
      <sec id="ph3.Management">
        <title>Management</title>
        <sec id="ph3.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with primary hyperoxaluria type 3 (PH3), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Kidney imaging for assessment of number and location of stones and presence of nephrocalcinosis</p>
            </list-item>
            <list-item>
              <p>Measurement of plasma oxalate concentration to assess the degree of oxalate overproduction</p>
            </list-item>
            <list-item>
              <p>Baseline 24-hour collection with measurement of oxalate, calcium, citrate, pH, urine volume, and other components of a supersaturation profile to identify specific risk factors for stones &#x02013; information that is valuable in guiding treatment</p>
            </list-item>
            <list-item>
              <p>Assessment of kidney function by serum creatinine and eGFR</p>
            </list-item>
            <list-item>
              <p>If chronic kidney disease (CKD) is present, evaluation for signs of systemic oxalosis by physical examination (livedo reticularis or non-healing ulcers of the skin), echocardiography (oxalate cardiomyopathy), electrocardiogram (conduction disturbances), complete blood count (erythropoietin-resistant anemia), bone films (sclerosis, pathologic fractures due to oxalate osteodystrophy), and retinal examination (retinal oxalate deposits)</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="ph3.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Reduction of urine supersaturation of calcium oxalate</bold> in order to reduce stone formation and formation of calcium oxalate crystals that can be injurious to the kidney:</p>
          <list list-type="bullet">
            <list-item>
              <p>Maintainance of high oral fluid intake (&#x0003e;2.5 L/m<sup>2</sup> BSA)</p>
            </list-item>
            <list-item>
              <p>Oral administration of an inhibitor of calcium oxalate crystallization. Most patients are treated with one of these agents, which include potassium and sodium citrate [<xref ref-type="bibr" rid="ph3.REF.leumann.2001.1986">Leumann &#x00026; Hoppe 2001</xref>], orthophosphate [<xref ref-type="bibr" rid="ph3.REF.milliner.1994.1553">Milliner et al 1994</xref>], or magnesium [<xref ref-type="bibr" rid="ph3.REF.watts.1994.593">Watts 1994</xref>]. Note: Simultaneous administration of citrate and phosphate should be done with caution due to the potential for increasing calcium phosphate supersaturation.</p>
            </list-item>
          </list>
          <p><bold>Avoidance of supersaturation of calcium oxalate in the blood.</bold> Although there is little experience with chronic kidney disease in PH3, a decline in GFR to less than approximately 40 mL/min/1.73m<sup>2</sup> would be expected to result in increased plasma oxalate and the potential for systemic oxalosis (as in other forms of PH). If plasma oxalate exceeds 35-50 &#x003bc;mol/L dialysis or transplantation is needed to reduce the risk of multiorgan complications of calcium oxalate deposition.</p>
          <p><bold>Prevention of stone complications</bold> through regular monitoring (see <xref ref-type="sec" rid="ph3.Surveillance">Surveillance</xref>) and prompt attention to the following, any of which can damage kidney function:</p>
          <list list-type="bullet">
            <list-item>
              <p>Alleviate obstruction of the urinary tract by a stone promptly through stent placement and/or stone removal.</p>
            </list-item>
            <list-item>
              <p>Maintain continuous fluid intake and urine flow before, during, and for several days after stone removal procedures.</p>
            </list-item>
            <list-item>
              <p>Treat urinary tract infections promptly and thoroughly, as bacteria may cause pyelonephritis or infect stones and complicate management.</p>
            </list-item>
          </list>
          <p><bold>Avoidance of acute kidney injury</bold> by avoiding intravascular volume contraction at all times. This may necessitate intravenous fluids during severe gastroenteritis or other circumstances in which oral fluid intake cannot be maintained.</p>
          <p><bold>Avoidance of marked dietary oxalate excess</bold>. Since the source of the excess oxalate in PH3 is metabolic overproduction, little is gained by strict low oxalate diets, which in young children may compromise nutrition. Simple avoidance of marked dietary oxalate excess is recommended.</p>
        </sec>
        <sec id="ph3.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="ph3.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="ph3.Surveillance">
          <title>Surveillance</title>
          <p>Attention to ongoing care, including adherence to high fluid intake and medication schedule, is essential to good outcomes.</p>
          <p>For patients who are stable and doing well* the following are recommended annually:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical assessment of stone-related symptoms including pain, frequency of passage of stones or gravel in the urine, and urinary tract infection</p>
            </list-item>
            <list-item>
              <p>Assessment of kidney function (serum creatinine and eGFR) and electrolytes</p>
            </list-item>
            <list-item>
              <p>Measurement of plasma oxalate concentration, particularly in those with any impairment of glomerular filtration rate (GFR)</p>
            </list-item>
            <list-item>
              <p>24 hour urine oxalate and supersaturation study. During follow up, changes in the urine supersaturation can be used to monitor the effectiveness of therapy by confirming that the crystallization potential has decreased.</p>
            </list-item>
            <list-item>
              <p>Renal ultrasound examination or other imaging to monitor for stone formation</p>
            </list-item>
          </list>
          <p>*Very young patients, those with complex stone problems, and those with reduced kidney function need closer management with more frequent assessments.</p>
        </sec>
        <sec id="ph3.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intravascular volume contraction (Note: Liberal use of intravenous fluids is indicated whenever oral fluid intake is inadequate.)</p>
            </list-item>
            <list-item>
              <p>Delays in treatment of acute stone episodes</p>
            </list-item>
            <list-item>
              <p>Nephrotoxic agents</p>
            </list-item>
            <list-item>
              <p>Marked dietary oxalate excess</p>
            </list-item>
            <list-item>
              <p>High-dose ascorbic acid</p>
            </list-item>
          </list>
        </sec>
        <sec id="ph3.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Using molecular genetic testing for the <italic toggle="yes">HOGA1</italic> pathogenic variants found in the proband, it is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from early treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>Urine oxalate should be measured in all sibs who are affected (i.e., have biallelic <italic toggle="yes">HOGA1</italic> pathogenic variants) or who are carriers (i.e., heterozygous for one <italic toggle="yes">HOGA1</italic> pathogenic variant)</p>
            </list-item>
            <list-item>
              <p>Any sib with elevated urine oxalate/creatinine ratio or elevated oxalate excretion rate corrected for 1.73 m<sup>2</sup> BSA should undergo kidney ultrasound examination, measurement of plasma oxalate concentration, a baseline 24-hour urine collection with a supersaturation profile, and measurement of serum creatinine concentration (see <xref ref-type="sec" rid="ph3.Evaluations_Following_Initial_Diagno">Evaluations Following Initial Diagnosis</xref>).</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="ph3.Related_Genetic_Counseling_Issues">Genetic Counselling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ph3.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>There have been no studies of pregnancy in women with PH3. However, most women with PH1 or PH2 who had good kidney function during pregnancy have done well and have delivered healthy infants [<xref ref-type="bibr" rid="ph3.REF.norby.2004.277">Norby &#x00026; Milliner 2004</xref>].</p>
          <p>Adequate fluid intake should be maintained throughout the pregnancy. Circumstances that compromise fluid intake, such as hyperemesis gravidarum, should prompt early initiation of IV fluid to maintain adequate hydration.</p>
          <p>Stones that become symptomatic during pregnancy may require routine (but specialized) techniques for management.</p>
          <p>In patients with stones, urinary tract infections should be treated promptly and thoroughly due to the potential for bacteria to cause pyelonephritis or infect stones and complicate management.</p>
        </sec>
        <sec id="ph3.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Humans cannot degrade oxalate; however, certain bacteria use oxalate as an energy source. Preliminary studies suggest that oral administration of <italic toggle="yes">O. formigenes</italic> could reduce oxalate excretion in individuals with PH. Two previous double blind studies were inconclusive [<xref ref-type="bibr" rid="ph3.REF.hoppe.2006.1305">Hoppe et al 2006</xref>]. A third clinical trial is under way in Europe, with results expected in 2015.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="ph3.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ph3.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Primary hyperoxaluria type 3 (PH3) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="ph3.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">HOGA1</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are usually asymptomatic; however, exceptions may occur (see <xref ref-type="sec" rid="ph3.Clinical_Description">Clinical Description</xref>, Heterozygotes).</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are usually asymptomatic; however, exceptions may occur (see <xref ref-type="sec" rid="ph3.Clinical_Description">Clinical Description</xref>, Heterozygotes).</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with PH3 are obligate heterozygotes (carriers) for a <italic toggle="yes">HOGA1</italic> pathogenic variant.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier (i.e., heterozygous) for a <italic toggle="yes">HOGA1</italic> pathogenic variant.</p>
        </sec>
        <sec id="ph3.Heterozygote_Carrier_Detection">
          <title>Heterozygote (Carrier) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">HOGA1</italic> pathogenic variants in the family<italic toggle="yes">.</italic></p>
        </sec>
        <sec id="ph3.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="ph3.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ph3.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">HOGA1</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p>While there is interest in prenatal testing in PH, especially in families with early renal failure, the interest in prenatal testing for PH3 is low given that the phenotype is usually relatively mild and renal failure is rare. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">HOGA1</italic> pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="ph3.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ph3.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The longest <italic toggle="yes">HOGA1</italic> transcript variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_138413.3">NM_138413.3</ext-link>) has a coding region of 981 bp encoded by seven exons. The genomic size of <italic toggle="yes">HOGA1</italic> is ~28.5 kb.</p>
        <p><italic toggle="yes">HOGA1</italic> was previously termed <italic toggle="yes">DHDPSL</italic> [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>, <xref ref-type="bibr" rid="ph3.REF.riedel.2011.e26021">Riedel et al 2011</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ph3" object-id="ph3.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> Approximately 40 different <italic toggle="yes">HOGA1</italic> pathogenic variants have been described [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>, <xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>, <xref ref-type="bibr" rid="ph3.REF.beck.2013.162">Beck et al 2013</xref>, <xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>]. (See <related-object source-id="gene" document-id="ph3" object-id="ph3.molgen.TA">Table A</related-object> for locus specific pathogenic variant databases.) The vast majority of individuals with PH3 have two pathogenic non-truncating <italic toggle="yes">HOGA1</italic> variants [<xref ref-type="bibr" rid="ph3.REF.hopp.2015.2559">Hopp et al 2015</xref>]; only one affected individual with two pathogenic truncating HOGA1 variants has been described [<xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>]. It is not known if this observation is significant.</p>
        <p>Two common pathogenic variants, an in-frame deletion and an atypical splicing event (<xref ref-type="table" rid="ph3.T.hoga1_pathogenic_variants_discusse">Table 3</xref>), account for nearly 75% of all pathogenic variants.</p>
        <list list-type="bullet">
          <list-item>
            <p>The p.Glu315del pathogenic variant is enriched in the Ashkenazi Jewish population [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>].</p>
          </list-item>
          <list-item>
            <p>The atypical splicing change, c.700+5G&#x0003e;T, results in an in-frame insertion of 51 bp [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>, <xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al 2012</xref>].</p>
          </list-item>
        </list>
        <table-wrap id="ph3.T.hoga1_pathogenic_variants_discusse" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p><italic toggle="yes">HOGA1</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.944_946delAGG&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu315del</td>
                <td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_138413.3">NM_138413.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_612422.2">NP_612422.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.700+5G&#x0003e;T&#x000a0;<sup>2,&#x000a0;3</sup></td>
                <td headers="hd_h_ph3.T.hoga1_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="ph3.TF.3.1">
              <label>1. </label>
              <p>
                <xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al [2010]</xref>
              </p>
            </fn>
            <fn id="ph3.TF.3.2">
              <label>2. </label>
              <p>In silico analysis predicted use of another donor splice site 51 nucleotides downstream resulting in an in-frame insertion of 17 amino acids [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>], subsequently confirmed in liver by <xref ref-type="bibr" rid="ph3.REF.williams.2012.3191">Williams et al [2012]</xref> and by illegitimate transcription from Epstein Barr virus-transformed lymphocytes [<xref ref-type="bibr" rid="ph3.REF.monico.2011.2289">Monico et al 2011</xref>].</p>
            </fn>
            <fn id="ph3.TF.3.3">
              <label>3. </label>
              <p>Pathogenic variant originally (incorrectly) described as c.701+4G&#x0003e;T [<xref ref-type="bibr" rid="ph3.REF.belostotsky.2010">Belostotsky et al 2010</xref>].</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> HOGA has 327 amino acids. Most of the protein (residues 38-321) has sequence homology with the TIM phosphate binding superfamily.</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants are thought to result in loss of (or at least reduced) function of the protein.</p>
      </sec>
      <sec id="ph3.References">
        <title>References</title>
        <sec id="ph3.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ph3.Literature_Cited.reflist0">
            <ref id="ph3.REF.allard.2015.1807">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allard</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leclerc</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cachat</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fichtner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Souza</surname>
                    <given-names>VC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camoin-Schweitzer</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva-Bourdain</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacchetta</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Renal function can be impaired in children with primary hyperoxaluria type 3.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>2015</year>
                <volume>30</volume>
                <fpage>1807</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">25972204</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.barratt.1991.501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barratt</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasidas</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murdoch</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Urinary oxalate and glycolate excretion and plasma oxalate excretion.</article-title>
                <source>Arch Dis Child.</source>
                <year>1991</year>
                <volume>66</volume>
                <fpage>501</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">2031609</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.beck.2013.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baasner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buescher</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habbig</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reintjes</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sikora</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mache</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pohl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stahl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toenshoff</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pape</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fehrenbach</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grohe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yigit</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salido</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2013</year>
                <volume>21</volume>
                <fpage>162</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">22781098</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.belostotsky.2012.1497">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Belostotsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria type III--a model for studying perturbations in glyoxylate metabolism.</article-title>
                <source>J Mol Med.</source>
                <year>2012</year>
                <volume>90</volume>
                <fpage>1497</fpage>
                <lpage>504</lpage>
                <pub-id pub-id-type="pmid">22729392</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.belostotsky.2010">
              <mixed-citation publication-type="other">Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87-392-9.</mixed-citation>
            </ref>
            <ref id="ph3.REF.campfield.1989.860">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Campfield</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braden</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Urinary oxalate excretion by very low birth weight infants receiving parenteral nutrition.</article-title>
                <source>Pediatrics</source>
                <year>1989</year>
                <volume>84</volume>
                <fpage>860</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">2508054</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.cochat.2013.649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria.</article-title>
                <source>N Engl J Med.</source>
                <year>2013</year>
                <volume>369</volume>
                <fpage>649</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">23944302</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.edvardsson.2013.1923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edvardsson</surname>
                    <given-names>VO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beara-Lasic</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anglani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palsson</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary causes of kidney stones and chronic kidney disease.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>2013</year>
                <volume>28</volume>
                <fpage>1923</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">23334384</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.gibbs.1969.901">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gibbs</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <article-title>The variation of urinary oxalate excretion with age.</article-title>
                <source>J Lab Clin Med.</source>
                <year>1969</year>
                <volume>73</volume>
                <fpage>901</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">4891815</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.habbig.2011.1278">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Habbig</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Nephrocalcinosis and urolithiasis in children.</article-title>
                <source>Kidney Int</source>
                <year>2011</year>
                <volume>80</volume>
                <fpage>1278</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">21956187</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.halbritter.2015.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Halbritter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baum</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hynes</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thwaites</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gucev</surname>
                    <given-names>ZS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spaneas</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porath</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braun</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wassner</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tasic</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sayer</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrandt</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis.</article-title>
                <source>J Am Soc Nephrol.</source>
                <year>2015</year>
                <volume>26</volume>
                <fpage>543</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">25296721</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.harambat.2011">
              <mixed-citation publication-type="other">Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol. 2011;2011:864580.</mixed-citation>
            </ref>
            <ref id="ph3.REF.hopp.2015.2559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hopp</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogal</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seide</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meek</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <article-title>Milliner DS3, Harris PC4; on behalf of the Rare Kidney Stone Consortium. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.</article-title>
                <source>J Am Soc Nephrol.</source>
                <year>2015</year>
                <volume>26</volume>
                <fpage>2559</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">25644115</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.hoppe.2006.1305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatter</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Unruh</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hesse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laube</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaul</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidhu</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.</article-title>
                <source>Kidney Int</source>
                <year>2006</year>
                <volume>70</volume>
                <fpage>1305</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">16850020</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.hoppe.2009.1264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>The primary hyperoxalurias.</article-title>
                <source>Kidney Int.</source>
                <year>2009</year>
                <volume>75</volume>
                <fpage>1264</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">19225556</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.hoppe.2012.3024">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2012</year>
                <volume>27</volume>
                <fpage>3024</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22851625</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.kumar.2011.654">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collazo-Clavell</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarr</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vrtiska</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <article-title>Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery.</article-title>
                <source>Surgery.</source>
                <year>2011</year>
                <month>May</month>
                <volume>149</volume>
                <issue>5</issue>
                <fpage>654</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">21295813</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.leumann.2001.1986">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leumann</surname>
                    <given-names>E.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>The primary hyperoxalurias.</article-title>
                <source>J Am Soc Nephrol</source>
                <year>2001</year>
                <volume>12</volume>
                <fpage>1986</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">11518794</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.matsumoto.2015">
              <mixed-citation publication-type="book">Matsumoto J, Milliner DS. Primary hyperoxaluria. In: Coe F, Worcester E, Lingeman J, Evan A, eds. <italic toggle="yes">Kidney Stones: A Multidisciplinary Approach to Diagnosis and Treatment</italic>. Philadelphia, PA: Jaypee Brothers Medical Publications. In review 2015.</mixed-citation>
            </ref>
            <ref id="ph3.REF.milliner.1994.1553">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eickholt</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <article-title>Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.</article-title>
                <source>N Engl J Med.</source>
                <year>1994</year>
                <volume>331</volume>
                <fpage>1553</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7969325</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.monico.2011.2289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belostotsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogal</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herges</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seide</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haley</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frishberg</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis.</article-title>
                <source>Clin J Am Soc Nephrol.</source>
                <year>2011</year>
                <volume>6</volume>
                <fpage>2289</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">21896830</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.monico.2007.1905">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monico</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwanz</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Comprehensive mutation screening in 55 type 1 primary hyperoxaluria probands shows feasibility of a gene-based diagnosis.</article-title>
                <source>J Am Soc Nephrol.</source>
                <year>2007</year>
                <volume>18</volume>
                <fpage>1905</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">17460142</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.morgenstern.1993.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morgenstern</surname>
                    <given-names>BZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simmons</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moyer</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <article-title>Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study.</article-title>
                <source>J Pediatr.</source>
                <year>1993</year>
                <volume>123</volume>
                <fpage>248</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">8345420</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.nogueira.2000.384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nogueira</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vuong</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouton</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maillard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchand</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bozon</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1.</article-title>
                <source>Human Mutation.</source>
                <year>2000</year>
                <volume>15</volume>
                <fpage>384</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10737993</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.norby.2004.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Norby</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <article-title>Outcomes and complications of pregnancy in women with primary hyperoxaluria.</article-title>
                <source>Am J Kidney Dis</source>
                <year>2004</year>
                <volume>43</volume>
                <fpage>277</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">14750093</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.riedel.2011.e26021">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riedel</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hantgan</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowther</surname>
                    <given-names>WT</given-names>
                  </name>
                </person-group>
                <article-title>Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria.</article-title>
                <source>PLoS One.</source>
                <year>2011</year>
                <volume>6</volume>
                <fpage>e26021</fpage>
                <pub-id pub-id-type="pmid">21998747</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.riedel.2012">
              <mixed-citation publication-type="other">Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012;1822:1544-52.</mixed-citation>
            </ref>
            <ref id="ph3.REF.rumsby.2001.1697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cregeen</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solomon</surname>
                    <given-names>LR</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria type 2 without L-glycericaciduria; is the disease under-diagnosed?</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2001</year>
                <volume>16</volume>
                <fpage>1697</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11477177</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.schellfeith.2010.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schell-Feith</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kist-van Holthe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Heijden</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <article-title>Nephrocalcinosis in preterm neonates.</article-title>
                <source>Pediatr Nephrol</source>
                <year>2010</year>
                <volume>25</volume>
                <fpage>221</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">18797936</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.tang.2015.623">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstralh</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vrtiska</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <article-title>Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria.</article-title>
                <source>Kidney Int.</source>
                <year>2015</year>
                <volume>87</volume>
                <fpage>623</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">25229337</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.von_schnakenburg.1994.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>von Schnakenburg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrd</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latta</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reusz</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graf</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodehl</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Determination of oxalate excretion in spot urines of healthy children by ion chromatography.</article-title>
                <source>Eur J Clin Chem Clin Biochem.</source>
                <year>1994</year>
                <volume>32</volume>
                <fpage>27</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8167190</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.watts.1994.593">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>RWE</given-names>
                  </name>
                </person-group>
                <article-title>Primary hyperoxaluria type 1.</article-title>
                <source>QJM</source>
                <year>1994</year>
                <volume>87</volume>
                <fpage>593</fpage>
                <lpage>600</lpage>
                <pub-id pub-id-type="pmid">7987654</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.williams.2015.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bagg</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandrovcova</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aitman</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rumsby</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing.</article-title>
                <source>Mol Genet Genomic Med.</source>
                <year>2015</year>
                <volume>3</volume>
                <fpage>69</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">25629080</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.williams.2012.3191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bockenhauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van't Hoff</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinha</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unwin</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>VIljoen A, Rumsby G. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2012</year>
                <volume>27</volume>
                <fpage>3191</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22391140</pub-id>
              </element-citation>
            </ref>
            <ref id="ph3.REF.worcester.2010.954">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Worcester</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coe</surname>
                    <given-names>FL</given-names>
                  </name>
                </person-group>
                <article-title>Calcium kidney stones.</article-title>
                <source>N Engl J Med</source>
                <year>2010</year>
                <volume>363</volume>
                <fpage>954</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">20818905</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ph3.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ph3.Author_Notes">
          <title>Author Notes</title>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.rarekidneystones.org/">The Rare Kidney Stone Consortium</ext-link>, funded by the NIDDK and CCATS, is a member of the Rare Disease Clinical Research Network of the National Institutes of Health. The Consortium maintains registries for patients with primary hyperoxaluria, enteric hyperoxaluria, cystinuria, Dent disease, and APRT deficiency. A biobank, protocols for genetic testing, and a number of other protocols are open to enrollment for patients with these diseases.</p>
        </sec>
        <sec id="ph3.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>24 September 2015 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>13 February 2015 (dsm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="ph3.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Algorithm for the diagnostic evaluation of primary hyperoxaluria in an affected individual1. Chronic kidney disease is defined as a glomerular filtration rate &#x0003c;50 mL/min/1.73 m<sup>2</sup>, or serum creatinine &#x02265;2x normal for age. 2. Urine oxalate-to-creatinine (Ox/Cr) ratios in healthy children vary continuously by age (see <xref ref-type="table" rid="ph3.T.random_urine_oxalatetocreatinine_o">Table 1</xref>).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ph3-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
